
Alimentary

Pharmacology

& Therapeutics

VOLUME 18 PAGES 1-1190 2003

Editors

R E Pounder and W L Peterson

Associate Editors

J M Rhodes and P Martin

International Editorial Board

Chairman: J-R Malagelada

R Arnold
A T R Axon
K D Bardhan
G Bianchi Porro
F K L Chan
H G Dammann
G Delle Fave
B M Fennerty
A G Fraser
J P Galmiche
N J Greenberger

S B Hanauer
C J Hawkey
P Hayes
H J F Hodgson
G J Holtmann
C W Howden
R H Hunt
D P Jewell
M A Kamm
P O Katz
K Kawai
E B Keefe
D A Kelly
K Kimura
G J Krejs
S K Lam

R Lambert
C B H W Lamers
M J S Langman
D A Lieberman
P Malfertheiner
D C Metz
M Mignon
R Moreno-Otero
S Okabe
C O'Morain
J M Pajares
D S Rampton
J Rask-Madsen
J Rodes
P Rutgeerts
P Schoenfeld

F Shanahan
R A Smallwood
A Sonnenberg
S J Spechler
E F Stange
V Stanghellini
R W Stockbrugger
J J Y Sung
A Terano
W J Tremaine
G N Tytgat
D Vaira
N Vakil
C M Wilcox
T L Wright
S-D Xiao



**Blackwell
Publishing**

© 2003 Blackwell Publishing
Published by Blackwell Publishing Ltd
101 George Street, Edinburgh EH2 3ES

Other Editorial Offices:

Blackwell Publishing, 9600 Garsington Rd, Oxford OX4 2DQ, UK
Blackwell Publishing, Inc, 350 Main Street, Malden, MA 02148, USA
Blackwell Publishing Asia, 550 Swanston St, Carlton South, Victoria 3053, Australia
Blackwell Munksgaard, 1 Rosenørns Allé, PO Box 227, DK-1502 Copenhagen V, Denmark
Blackwell Verlag, Kurfürstendamm 57, D-10707 Berlin (Charlottenburg), Germany
Blackwell Publishing, 10 rue Casimir Delavigne, 75005 Paris, France
Blackwell Publishing KK, Healthcare Division, NK Bldg, 3F, 2-8-12 Iwamotocho, Chiyodaku, Tokyo 101-0032, Japan

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Centre (CCC) Transactional Reporting Service, provided that the base fee of \$15.00 per copy is paid directly to CCC, 222 Rosewood Drive, Suite 910, Danvers, MA 01973, USA. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale. Special requests should be addressed to the Editor, *Alimentary Pharmacology & Therapeutics*, ISSN 0269-2813/03 \$15.00

Alimentary Pharmacology & Therapeutics is included in the major information retrieval systems, including Index Medicus and Medline, the CINAHL index, CABS Science Citation Index, Current Contents—Life Sciences, Excerpta Medica and Current Opinion in Gastroenterology

ISSN 0269-2813
Typeset by SPS, Chennai, India
Printed and bound by Bell & Bain, Glasgow, UK

Contents

VOLUME 18 NUMBER 1 1st JULY

- 1 Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. *D. Gui, S. Rossi, M. Runfola & S. C. Magalini*
- 17 Review article: mitogen-activated protein kinases in chronic intestinal inflammation — targeting ancient pathways to treat modern diseases. *G. H. Waetzig & S. Schreiber*
- 33 Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. *E. B. Haagsma, A. P. Van Den Berg, J. H. Kleibeuker, M. J. H. Slooff & G. Dijkstra*
- 45 Inhibitory effect of probiotic *Escherichia coli* strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive *E. coli* strains isolated from patients with Crohn's disease. *J. Boudeau, A.-L. Glasser, S. Julien, J.-F. Colombel & A. Darfeuille-Michaud*
- 57 Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. *D. Kurnik, R. Loebstein, E. Fishbein, S. Almog, H. Halkin, S. Bar-Meir & Y. Chowers*
- 65 Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. *T. J. Creed, M. R. Norman, C. S. J. Probert, R. F. Harvey, I. S. Shaw, J. Smithson, J. Anderson, M. Moorghen, J. Gupta, N. A. Shepherd, C. M. Dayan & S. D. Hearing*
- 77 Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. *S. P. Dunlop, D. Jenkins, K. R. Neal, J. Naesdal, M. Borgaonker, S. M. Collins & R. C. Spiller*
- 85 Is a 9-month treatment sufficient in tuberculous enterocolitis? A prospective, randomized, single-centre study. *S. G. Kim, J. S. Kim, H. C. Jung & I. S. Song*
- 93 *Helicobacter pylori* eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. *T.-U. Wheeldon, T. T. H. Hoang, D. C. Phung, A. Björkman, M. Granström & M. Sörberg*
- 101 High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for *Helicobacter pylori* infection. *H. Isomoto, K. Inoue, H. Furusu, A. Enjoji, C. Fujimoto, M. Yamakawa, Y. Hirakata, K. Omagari, Y. Mizuta, K. Murase, S. Shimada, I. Murata & S. Kohno*
- 109 Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. *R. J. F. Laheij, L. G. M. van Rossum, J. B. M. J. Jansen & F. W. A. Verheugt*
- 117 Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? *E. Bolling-Sternevald, K. Lauritsen, N. J. Talley, O. Junghard & H. Glise*
- 125 A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. *J. L. Goldstein, A. J. Kivitz, K. M. Verburg, D. P. Recker, R. C. Palmer & J. D. Kent*
- 133 Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor. *J. D. Gardner, S. Sloan, M. Robinson & P. B. Miner Jr*
- 141 Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. *D. A. Revicki, A. M. Rentz, D. Dubois, P. Kahrilas, V. Stanghellini, N. J. Talley & J. Tack*
- 151 The effect of metoclopramide on QT dynamicity: double-blind, placebo-controlled, cross-over study in healthy male volunteers. *E. Elfidokuz & D. Kaya*

VOLUME 18 NUMBER 2 15TH JULY

- 157 Review article: current therapeutic options for gastric antral vascular ectasia. *S. Sebastian, C. A. O'Morain & M. J. M. Buckley*
- 167 Systematic review and meta-analysis: does gall-bladder ejection fraction on cholecystokinin cholescintigraphy predict outcome after cholecystectomy in suspected functional biliary pain? *S. Delgado-Aros, F. Cremonini, A. J. Bredenoord & M. Camilleri*
- 175 Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. *J.-M. Gornet, S. Couve, Z. Hassani, J.-C. Delchier, P. Marteau, J. Cosnes, Y. Bouhnik, J.-L. Dupas, R. Modigliani, F. Taillard & M. Lemann*
- 183 High variation of tioguanine absorption in patients with chronic active Crohn's disease. *P. Deibert, K. Dilger, C. Fischer, U. Hofmann, S. Nauck, S. Stoelben & W. Kreisel*
- 191 Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. *M. J. Shale & S. A. Riley*
- 199 Differential effects of baclofen on lower oesophageal sphincter pressure and proximal gastric motility in humans. *K.-J. Lee, R. Vos, J. Janssens & J. Tack*
- 209 Antibiotic prophylaxis for percutaneous endoscopic gastrostomy — a prospective, randomised, double-blind trial. *I. Ahmad, A. Mouncher, A. Abdoolah, R. Stenson, J. Wright, A. Daniels, J. Tillett, A. B. Hawthorne & G. Thomas*
- 217 Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease. *K. K. C. Lee, J. H. S. You, J. T. S. Ho, B. Y. Suen, M. Y. Yung, W. H. Lau, V. W. Y. Lee, J. Y. Sung & F. K. L. Chan*
- 223 What is the long-term outcome of the different subgroups of functional dyspepsia? *M. Heikkinen & M. Färkkilä*
- 231 Coeliac disease presenting with symptoms of irritable bowel syndrome. *B. Shahbazkhani, M. Forootan, S. Merat, M. R. Akbari, S. Nasserimoghadam, H. Vahedi & R. Malekzadeh*
- 237 Preliminary evaluation of an injectable anal sphincter bulking agent (Durasphere) in the management of faecal incontinence. *K. Davis, D. Kumar & J. Poloniecki*
- 245 The long-term effect of *Helicobacter pylori* eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. *T. Kamada, K. Haruma, J. Hata, H. Kusunoki, A. Sasaki, M. Ito, S. Tanaka & M. Yoshihara*

VOLUME 18 NUMBER 3 1ST AUGUST

- 253 Review article: the management of acute variceal bleeding. J. W. Ferguson, D. Tripathi & P. C. Hayes
- 263 Review article: mild to moderate Crohn's disease – defining the basis for a new treatment algorithm. W. J. Sandborn & B. G. Feagan
- 279 Meta-analysis: the relationship between *Helicobacter pylori* infection and gastro-oesophageal reflux disease. F. Cremonini, S. Di Caro, S. Delgado-Aros, A. Sepulveda, G. Gasbarrini, A. Gasbarrini & M. Camilleri
- 291 Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. G. N. Tytgat, R. C. Heading, S. Müller-Lissner, M. A. Kamm, J. Schölmerich, A. Berstad, M. Fried, S. Chaussade, D. Jewell & A. Briggs
- 303 Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. C. K. Rayner, G. McCormack, A. V. Emmanuel & M. A. Kamm
- 309 The mechanisms of prednisone inhibition of inflammation in Crohn's disease involve changes in intestinal permeability, mucosal TNF α production and nuclear factor kappa B expression. G. E. Wild, K. A. Waschke, A. Bitton & A. B. R. Thomson
- 319 Coping strategies, illness perception, anxiety and depression of patients with idiopathic constipation: a population-based study. C. Cheng, A. O. O. Chan, W. M. Hui & S. K. Lam
- 327 Pre-medication with pronase reduces artefacts during endoscopic ultrasonography. N. Sakai, M. Tatsuta, H. Iishi & A. Nakaizumi
- 333 CCK-1 receptor blockade for treatment of biliary colic: a pilot study. A. Malesci, R. Pezzilli, M. D'Amato & L. Rovati
- 339 Double-blinded placebo-controlled study of *Phyllanthus urinaris* for the treatment of chronic hepatitis B. H. L.-Y. Chan, J. J.-Y. Sung, W.-F. Fong, A. M.-L. Chim, P.-P. Yung, A. Y. Hui, K.-P. Fung & P.-C. Leung
- 347 Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of *Helicobacter pylori*. C.-H. Chi, C.-Y. Lin, B.-S. Sheu, H.-B. Yang, A.-H. Huang & J.-J. Wu

VOLUME 18 NUMBER 4 15TH AUGUST

- 357 Review article: nutritional therapy in alcoholic liver disease. *F. Stickel, B. Hoehn, D. Schuppan & H. K. Seitz*
- 375 Review article: pharmacological rationale for the use of somatostatin and analogues in portal hypertension. *H. Reynaert & A. Geerts*
- 387 Systematic review: health-related quality of life in functional dyspepsia. *H. B. El-Serag & N. J. Talley*
- 395 Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. *R. B. Gearry, M. L. Barclay, M. J. Burt, J. A. Collett, B. A. Chapman, R. L. Roberts & M. A. Kennedy*
- 401 Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. *B. Bonaz, J. Boitard, P. Marteau, M. Lémann, B. Coffin, B. Flourié, J. Belaiche, G. Cadiot, E.-H. Metman, A. Cortot & J.-F. Colombel & Getaid*
- 409 Hydrostatic balloon dilatation of Crohn's strictures. *J.-M. Sabaté, J. Villarejo, Y. Bouhnik, M. Allez, J.-M. Gornet, K. Vahedi, R. Modigliani & M. Lémann*
- 415 Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. *C. Högenauer, H. H. Wenzl, T. A. Hinterleitner & W. Petritsch*
- 425 Response to infliximab is related to disease duration in paediatric Crohn's disease. *P. Lionetti, F. Bronzini, C. Salvestrini, C. Bascietto, R. Berni Canani, G. L. Dé Angelis, G. Guariso, S. Martelossi, B. Papadatou & A. Barabino*
- 433 Essential fatty acid status in paediatric Crohn's disease: relationship with disease activity and nutritional status. *T. M. Trebble, S. A. Wootton, A. May, M. D. S. Erlewyn-Lajeunesse, A. Chakraborty, M. A. Mullee, M. A. Stroud & R. M. Beattie*
- 443 High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. *F. H. Ng, S. Y. Wong, C. M. Chang, W. H. Chen, C. Kng, A. I. Lanas & B. C. Y. Wong*

VOLUME 18 NUMBER 5 1st SEPTEMBER

- 451 Systematic review: hepatotoxic events associated with herbal medicinal products. *M. H. Pittler & E. Ernst*
- 473 Review article: a medicine based on cell transplantation – is there a future for treating liver diseases?
C. Di Campli, G. Gasbarrini & A. Gasbarrini
- 481 Evaluation of *Helicobacter* species in inflammatory bowel disease. *S. J. Bell, S. A. Chisholm, R. J. Owen, S. P. Borriello & M. A. Kamm*
- 487 Azathioprine and prednisone combination therapy in refractory coeliac disease. *M. S. Goerres, J. W. R. Meijer, P. J. Wahab, J. A. M. Kerckhaert, P. J. T. A. Groenen, J. H. J. M. van Krieken & C. J. J. Mulder*
- 495 The effect of *Lactobacillus plantarum* 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects. *D. Goossens, D. Jonkers, M. Russel, E. Stobberingh, A. van den Bogaard & R. Stockbrügger*
- 507 Effects of asimadoline, a κ -opioid agonist, on satiation and postprandial symptoms in health. *S. Delgado-Aros, H. J. Chial, F. Cremonini, I. Ferber, S. McKinzie, D. D. Burton & M. Camilleri*
- 515 Lack of efficacy of botulinum toxin in chronic anal fissure. *L. Siprodhis, V. Sébille, F. Pigot, P. Hémerly, F. Juguet & E. Bellissant*
- 525 Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. *C. Calabrese, A. Fabbri, M. Bortolotti, G. Cenacchi, A. Areni, C. Scialpi, M. Miglioli & G. Di Febo*
- 533 Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects. *C. Rordorf, N. Kellett, S. Mair, M. Ford, S. Milosavljev, J. Branson & G. Scott*
- 543 Letters to the Editors. *E. Gené, X. Calvet, R. Azagra, J. P. Gisbert, S. C. Howell, G. D. Eslick, T. Sugiyama, M. Asaka, M. Sozzi, D. M. M. Queiroz, A. G. Oliveira, J. B. Guerra, J. C. P. Lima, C. P. Silva & G. A. Rocha*

VOLUME 18 NUMBER 6 15TH SEPTEMBER

- 549 Review article: type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. P. Fabris, A. Floreani, G. Tositti, D. Vergani, F. de Lalla & C. Betterle
- 559 Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. N. Vakil & M. B. Fennerty
- 569 Consensus report: clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. E. Corazzari, P. Bytzer, M. Delvaux, G. Holtmann, J. R. Malagelada, J. Morris, S. Muller-Lissner, R. C. Spiller, J. Tack & P. J. Whorwell
- 581 Esomeprazole administered through a nasogastric tube provides bioavailability similar to oral dosing. M. B. Sostek, Y. Chen, W. Skammer, H. Winter, J. Zhao & T. Andersson
- 587 Once-daily pantoprazole 40 mg and esomeprazole 40mg have equivalent overall efficacy in relieving GERD-related symptoms. T. Scholten, G. Gatz & U. Hole
- 595 Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. W. M. Wong, K. C. Lai, K. F. Lam, W. M. Hui, W. H. C. Hu, C. L. K. Lam, H. H. X. Xia, J. Q. Huang, C. K. Chan, S. K. Lam & B. C. Y. Wong
- 605 Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease. M. Cicala, S. Emerenziani, R. Caviglia, M. P. L. Guarino, P. Vavassori, M. Ribolsi, S. Carotti, T. Petitti & F. Pallone
- 615 *Helicobacter pylori* eradication is beneficial in the treatment of functional dyspepsia. P. Malfertheiner, J. Mössner, W. Fischbach, P. Layer, A. Leodolter, M. Stolte, K. Demleitner & W. Fuchs
- 627 Levofloxacin-based triple therapy vs. quadruple therapy in second-line *Helicobacter pylori* treatment: a randomized trial. E. C. Nista, M. Candelli, F. Cremonini, I. A. Cazzato, S. Di Caro, M. Gabrielli, L. Santarelli, M. A. Zocco, V. Ojetti, E. Carloni, G. Cammarota, G. Gasbarrini & A. Gasbarrini
- 635 What is the role of serology in assessing *Helicobacter pylori* eradication? B. Bergey, P. Marchildon, J. Peacock & F. Mégraud
- 641 Sequential treatment for *Helicobacter pylori* eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. C. Hassan, V. De Francesco, A. Zullo, G. Scaccianoce, D. Piglionica, E. Ierardi, C. Panella & S. Morini
- 647 Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for *Helicobacter pylori* eradication. M. Vergara, M. Vallve, J. P. Gisbert & X. Calvet
- 655 No volume effect on retrograde colonic spread of rectally-administered ropivacaine gel. E. Arlander, T. Cederlund & K. Måre

VOLUME 18 NUMBER 7 1st OCTOBER

- 661 Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C. A. Zaman, M. B. Fennerty & E. B. Keeffe
- 671 Systematic review: the economic impact of irritable bowel syndrome. J. M. Inadomi, M. B. Fennerty & D. Bjorkman
- 683 Review article: colorectal cancer chemotherapy. S. Gill, R. R. Thomas & R. M. Goldberg
- 693 Detection of oxidative DNA damage in oesophageal biopsies of patients with reflux symptoms and normal pH monitoring. L. Liu, G. Ergun, A. Ertan, K. Woods, I. Sachs & M. Younes
- 699 Effect of non-selective γ -aminobutyric acid receptor stimulation on motor function of the lower oesophageal sphincter and gastro-oesophageal reflux in healthy human subjects. P. Cantù, S. Carmagnola, D. Savojardo, M. Allocca & R. Penagini
- 705 Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. D. Armstrong, D. Bair, C. James, L. Tanser, S. Escobedo & K. Nevin
- 713 Analysis of the meal-dependent intragastric performance of a gastric-retentive tablet assessed by magnetic resonance imaging. A. Steingoetter, P. Kunz, D. Weishaupt, K. Mäder, H. Lengsfeld, M. Thumshirn, P. Boesiger, M. Fried & W. Schwizer
- 721 Inulin is an ideal substrate for a hydrogen breath test to measure the oro-caecal transit time. K. P. Geboes, A. Luybaerts, P. Rutgeerts & K. Verbeke
- 731 Cyclo-oxygenase-2 over-expression in sporadic colorectal carcinoma without lymph node involvement. B. Buecher, M.-F. Heymann, A. Lièvre, J.-M. Nguyen, K. Wilson, S. Béziau, J.-F. Mosnier, J.-P. Galmiche & H. M. Blottière
- 741 Infliximab in the treatment of medically refractory indeterminate colitis. K. A. Papadakis, L. Treyzon, M. T. Abreu, P. R. Fleshner, S. R. Targan & E. A. Vasiliauskas
- 749 Small bowel stenosis in Crohn's disease: clinical, biochemical and ultrasonographic evaluation of histological features. G. Maconi, L. Carsana, P. Fociani, G. M. Sampietro, S. Ardizzone, M. Cristaldi, F. Parente, G. L. Vago, A. M. Taschieri & G. Bianchi Porro

- 757 Meta-analysis: proton pump inhibitors vs. H₂-receptor antagonists — their efficacy with antibiotics in *Helicobacter pylori* eradication. J. P. Gisbert, S. Khorrami, X. Calvet, R. Gabriel, F. Carballo & J. M. Pajares
- 767 Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease — an analysis based on the ProGERD initiative. M. Kulig, A. Leodolter, M. Vieth, E. Schulte, D. Jaspersen, J. Labenz, T. Lind, W. Meyer-Sabellek, P. Malfertheiner, M. Stolte & S. N. Willich
- 777 Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis. P. Schiedermaier, L. Koch, B. Stoffel-Wagner, G. Layer & T. Sauerbruch
- 785 ¹³C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. A. Petrolati, D. Festi, G. De Berardinis, L. Colaiocco-Ferrante, D. Di Paolo, G. Tisone & M. Angelico
- 791 Second-line treatment for failure to eradicate *Helicobacter pylori*: a randomized trial comparing four treatment strategies. H. Lamouliatte, F. Mégraud, J.-C. Delchier, J.-F. Bretagne, A. Courillon-Mallet, J.-D. De Korwin, J.-L. Fauchère, A. Labigne, J.-F. Fléjou & P. Barthelemy (for a Multicentre Study Group)
- 799 Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating *Helicobacter pylori* in the absence of antimicrobial resistance. S. Miehke, W. Schneider-Brachert, E. Bästlein, S. Ebert, C. Kirsch, C. Haferland, M. Buchner, M. Neumeyer, M. Vieth, M. Stolte, N. Lehn & E. Bayerdörffer
- 805 Favourable effect of regular intake of fermented milk containing *Lactobacillus johnsonii* on *Helicobacter pylori* associated gastritis. D. Pantoflickova, I. Corthésy-Theulaz, G. Dorta, M. Stolte, P. Isler, F. Rochat, M. Enslen & A. L. Blum
- 815 Randomized study of different 'second-line' therapies for *Helicobacter pylori* infection after failure of the standard 'Maastricht triple therapy'. F. Perri, V. Festa, A. Merla, F. Barberani, A. Pilotto & A. Andriulli
- 821 Role of antibiotic sensitivity testing before first-line *Helicobacter pylori* eradication treatments. M. Neri, A. Milano, F. Laterza, G. Di Bonaventura, R. Piccolomini, M. P. Caldarella, C. Balatsinou, D. Lapenna & F. Cuccurullo
- 829 Lansoprazole reduces ulcer relapse after eradication of *Helicobacter pylori* in nonsteroidal anti-inflammatory drug users — a randomized trial. K. C. Lai, S. K. Lam, K. M. Chu, W. M. Hui, K. F. Kwok, B. C. Y. Wong, H. C. Hu, W. M. Wong, O. O. Chan & C. K. Chan
- 837 Expression of carbonic anhydrase IX in human pancreatic cancer. M. Juhász, J. Chen, U. Lendeckel, U. Kellner, H.-U. Kasper, Z. Tulassay, S. Pastorekova, P. Malfertheiner & M. P. A. Ebert
- 847 Gastric acid-suppressive therapy and community-acquired respiratory infections. R. J. F. Laheij, M. C. Van Ijzendoorn, M. J. R. Janssen & J. B. M. J. Jansen

VOLUME 18 NUMBER 9 1st NOVEMBER

- 853 Review article: oral and intestinal mucositis — causes and possible treatments. *M. Duncan & G. Grant*
- 875 Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. *P. O. Katz, D. O. Castell & D. Levine*
- 883 Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. *N. D. Pehlivanov, M. Olyae, I. Sarosiek & R. W. McCallum*
- 891 The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. *J. D. Gardner, H. Gallo-Torres, S. Sloan, M. Robinson & P. B. Miner Jr*
- 907 Development and validation of a disease-specific treatment satisfaction questionnaire for gastro-oesophageal reflux disease. *K. S. Coyne, I. Wiklund, J. Schmier, K. Halling, A. Degl' Innocenti & D. Revicki*
- 917 Drug interaction between infliximab and azathioprine in patients with Crohn's disease. *X. Roblin, F. Serre-Debeauvais, J.-M. Phelip, G. Bessard & B. Bonaz*
- 927 European multicentre validation trial of two new non-invasive tests for the detection of *Helicobacter pylori* antibodies: urine-based ELISA and rapid urine test. *A. Leodolter, D. Vaira, F. Bazzoli, K. Schütze, A. Hirschl, F. Mégraud & P. Malfertheiner*
- 933 Re-treatment of patients with anti-HBe-positive chronic hepatitis B who relapsed after an initial course of lamivudine. *G. A. Niro, T. Santantonio, R. Fontana, M. Insalata, D. Facciorusso, F. Signorile, F. Perri, A. Guastadisegni, D. Gioffreda, O. Palmieri, G. Pastore & A. Andriulli*
- 941 A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. *B. C.-Y. Wong, W. M. Wong, K. L. Cheung, T. S. M. Tong, P. Rozen, G. P. Young, K. W. Chu, J. Ho, W. L. Law, H. M. Tung, K. C. Lai, W. H. C. Hu, C. K. Chan & S. K. Lam*
- 947 Letter to the Editors. *I. L. P. Beales & J. McGovern*

VOLUME 18 NUMBER 10 15TH NOVEMBER

- 949 Review article: oral ulceration – aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic. *E. A. Field & R. B. Allan*
- 963 Systematic review: ursodeoxycholic acid — adverse effects and drug interactions. *W. Hempfling, K. Dilger & U. Beuers*
- 973 Is there any association between myocardial infarction, gastro-oesophageal reflux disease and acid-suppressing drugs? *S. Johansson, M.-A. Wallander, A. Ruigómez & L. A. García Rodríguez*
- 979 The impact of current tobacco use on the outcome of paracetamol poisoning. *L. E. Schmidt & K. Dalhoff*
- 987 How patients manage gastrointestinal symptoms after pelvic radiotherapy. *B. Gami, K. Harrington, P. Blake, D. Dearnaley, D. Tait, J. Davies, A. R. Norman & H. J. N. Andreyev*
- 995 The utility of the ^{13}C -galactose breath test as a measure of liver function. *S. Saadeh, P. W. Behrens, M. A. Parsi, W. D. Carey, J. T. Connor, M. Grealis & D. S. Barnes*
- 1003 Fistula response to methotrexate in Crohn's disease: a case series. *U. Mahadevan, J. F. Marion & D. H. Present*
- 1009 Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel. *F. Parente, S. Greco, M. Molteni, C. Cucino, G. Maconi, G. M. Sampietro, P. G. Danelli, M. Cristaldi, R. Bianco, S. Gallus & G. Bianchi Porro*
- 1017 Low and high doses of rabeprazole vs. omeprazole for cure of *Helicobacter pylori* infection. *C. Kositchaiwat, B. Ovarlarnporn, U. Kachintorn & K. Atisook*
- 1023 Three-day intravenous triple therapy is not effective for the eradication of *Helicobacter pylori* infection in patients with bleeding gastro-duodenal ulcer. *M. Romero-Gómez, C. Martínez-Delgado, P. Hergueta, J.-M. Navarro, A. Garrido-Serrano, O. Santos & C. Montojo*
- 1031 Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. *J. Tack, R. Vos, J. Janssens, J. Salter, S. Jauffret & G. Vandeplasseche*
- 1039 Effect of a novel 5-HT₃ receptor agonist on upper gastrointestinal motility in humans. *N. S. Coleman, L. Marciani, E. Blackshaw, J. Wright, M. Parker, T. Yano, S. Yamazaki, P. Q. Chan, K. Wilde, P. A. Gowland, A. C. Perkins & R. C. Spiller*

VOLUME 18 NUMBER 11/12 DECEMBER

- 1049 Review article: chemotherapy for pancreatic cancer.
*S. Shore, M. G. T. Raraty, P. Ghaneh
& J. P. Neoptolemos*
- 1071 Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. *F. Fabrizi, G. Dulai, V. Dixit, S. Bunnapradist & P. Martin*
- 1083 Assessment of oesophageal motor function in patients with dysphagia or chest pain — the Clinical Outcomes Research Initiative experience. *R. Dekel, T. Pearson, C. Wendel, P. De Garmo, M. B. Fennerty & R. Fass*
- 1091 Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease.
M. Frazzoni, E. De Micheli & V. Savarino
- 1099 Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. *G. Holtmann, B. Adam, S. Haag, W. Collet, E. Grünewald & T. Windeck*
- 1107 Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. *F. Castiglione, A. Riso, E. Di Girolamo, A. Cozzolino, F. Manguso, R. Grassia & G. Mazzacca*
- 1113 Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. *C. Dejaco, M. Harter, T. Waldhoer, W. Miehsler, H. Vogelsang & W. Reinisch*
- 1121 A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. *S. A. Bartram, R. T. Peaston, D. J. Rawlings, R. M. Francis & N. P. Thompson*
- 1129 Nutcracker oesophagus: a double-blind, placebo-controlled, cross-over study of the effects of lansoprazole. *M. Borjesson, P. Rohny, C. Mannheimer & M. Pilhall*
- 1137 Adherence to proton pump inhibitors or H₂-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. *M. C. J. M. Sturkenboom, T. A. Burke, M. J. D. Tangelder, J. P. Dieleman, S. Walton & J. L. Goldstein*
- 1149 Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H₂-receptor antagonist. *T. Shimatani, M. Inoue, T. Kuroiwa, Y. Horikawa, H. Mieno & M. Nakamura*
- 1159 Current patterns of irritable bowel syndrome in Taiwan: the Rome II questionnaire on a Chinese population. *C.-L. Lu, C.-Y. Chen, H.-C. Lang, J.-C. Luo, S.-S. Wang, F.-Y. Chang & S.-D. Lee*
- 1171 Letters to the Editors. *M. Madalinski and L. Siproudhis & E. Bellissant and A. Matsumoto, T. Izumiya, K. Takimoto & H. Inokuchi and S. Rajendra, J. J. Ho and T. Furuta, N. Shirai, M. Sugimoto, K. Ohashi & T. Ishizaki and M. Candelli, I. A. Cazzato, E. C. Nista, G. Pignataro & A. Gasbarrini*